TransMedics Group TMDX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
TransMedics Group (TMDX) Business Model and Operations Summary
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Key Insights
TransMedics Group (TMDX) Core Market Data and Business Metrics
Latest Closing Price
$68.27Market Cap
$2.31 BillionPrice-Earnings Ratio
73.41Total Outstanding Shares
33.66 Million SharesTotal Employees
728Dividend
No dividendIPO Date
May 2, 2019SIC Description
Electromedical & Electrotherapeutic ApparatusPrimary Exchange
NASDAQHeadquarters
200 Minuteman Road, Andover, MA, 01810
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $22.61 Million |
| Net Cash Flow From Investing Activities, Continuing | $-157.51 Million |
| Net Cash Flow, Continuing | $-97.46 Million |
| Net Cash Flow From Investing Activities | $-157.51 Million |
| Net Cash Flow From Financing Activities, Continuing | $22.61 Million |
| Net Cash Flow | $-97.02 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Operating Expenses | $206.54 Million |
| Costs And Expenses | $368.44 Million |
| Diluted Earnings Per Share | $0.93 |
| Diluted Average Shares | $35.26 Million |
| Selling, General, and Administrative Expenses | $156.27 Million |
| Nonoperating Income/Loss | $1.20 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $29,000 |
| Comprehensive Income/Loss | $32.67 Million |
| Comprehensive Income/Loss Attributable To Parent | $32.67 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Current Liabilities | $26.15 Million |
| Noncurrent Liabilities | $515.60 Million |
| Current Liabilities | $60.05 Million |
| Inventory | $52.15 Million |
| Equity Attributable To Parent | $209.92 Million |
| Intangible Assets | $2.20 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||